Hiroaki Shizuya
Fondateur chez Aliva Biopharmaceuticals, Inc.
Profil
Hiroaki Shizuya is the founder of Aliva Biopharmaceuticals, Inc. (founded in 2002) and Ablexis LLC (founded in 2009).
He was a member of the California Institute of Technology.
He earned a doctorate degree from Keio University.
Postes actifs de Hiroaki Shizuya
| Sociétés | Poste | Début |
|---|---|---|
Aliva Biopharmaceuticals, Inc.
 Aliva Biopharmaceuticals, Inc. Pharmaceuticals: GenericHealth Technology Aliva Biopharmaceuticals, Inc. is building the next generation animal systems for accurate prediction in human drug profiling at the pre-clinical stage with its BAC (Bacterial Artificial Chromosome) based genome engineering technology. In addition, Aliva's technology platform provides animal models that mimic serious human functional and infectious diseases for assessing effectiveness of new therapeutics prior to selecting a lead compound for Phase I testing. This technology will also be applicable for assessing the drug response of people with small genetic differences, which would allow matching drug candidates with appropriate patient populations. | Fondateur | 03/06/2010 |
Anciens postes connus de Hiroaki Shizuya
| Sociétés | Poste | Fin |
|---|---|---|
California Institute of Technology
 California Institute of Technology Other Consumer ServicesConsumer Services California Institute of Technology provides education focusing on science, engineering, academia, business, and public service. The company was founded in 1891 and it is headquartered in Pasadena, CA. | Corporate Officer/Principal | - |
Ablexis LLC
 Ablexis LLC Packaged SoftwareTechnology Services Ablexis LLC develops next-generation platform for antibody drug discovery. It develops the AlivaMab Mouse, an innovative, next-generation transgenic mouse platform intended to enable the efficient discovery and development of the next generation of human therapeutic antibodies. The company was founded by Green L. Larry and Hiroaki Shizuya in December 2009 and is headquartered in Burlingame, CA. | Fondateur | - |
Formation de Hiroaki Shizuya
| Keio University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Aliva Biopharmaceuticals, Inc.
Aliva Biopharmaceuticals, Inc. Pharmaceuticals: GenericHealth Technology Aliva Biopharmaceuticals, Inc. is building the next generation animal systems for accurate prediction in human drug profiling at the pre-clinical stage with its BAC (Bacterial Artificial Chromosome) based genome engineering technology. In addition, Aliva's technology platform provides animal models that mimic serious human functional and infectious diseases for assessing effectiveness of new therapeutics prior to selecting a lead compound for Phase I testing. This technology will also be applicable for assessing the drug response of people with small genetic differences, which would allow matching drug candidates with appropriate patient populations. | Health Technology |
Ablexis LLC
Ablexis LLC Packaged SoftwareTechnology Services Ablexis LLC develops next-generation platform for antibody drug discovery. It develops the AlivaMab Mouse, an innovative, next-generation transgenic mouse platform intended to enable the efficient discovery and development of the next generation of human therapeutic antibodies. The company was founded by Green L. Larry and Hiroaki Shizuya in December 2009 and is headquartered in Burlingame, CA. | Technology Services |
